Takeaway
While cerebrospinal fluid (CSF) tau increases with age as a result of normal aging, this biomarker decreases with age for those with Alzheimer’s disease (AD).
Why this matters
CSF total tau (t-tau) and phosphorylated tau (p-tau) may be useful biomarkers for AD in clinical trials.